New drug combo shows promise in early cancer trial
NCT ID NCT04282018
First seen Mar 07, 2026 · Last updated Jun 18, 2026 · Updated 17 times
Summary
This early-phase study tested a new drug called BGB-10188, alone or combined with other cancer drugs, in 97 people with certain blood cancers or advanced solid tumors. The goal was to find safe doses and check for side effects. The study was completed, but the ideal dose for some combinations could not be determined due to limited data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, 200032, China
-
Austin Health
Heidelberg, Victoria, 3084, Australia
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, 2148, Australia
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200000, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Gallipoli Medical Research Foundation
Greenslopes, Queensland, 4120, Australia
-
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, 750004, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Jining No Peoples Hospital West Branch
Jining, Shandong, 272000, China
-
Monash Health
Clayton, Victoria, 3168, Australia
-
Peking University Shenzhen Hospital
Shenzhen, Guangdong, 518036, China
-
Perth Blood Institute
West Perth, Western Australia, 6005, Australia
-
Pindara Private Hospital
Benowa, Queensland, 4217, Australia
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
Saint Vincents Hospital Sydney
Darlinghurst, New South Wales, 2010, Australia
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Third Xiangya Hospital of Central South University
Changsha, Hunan, 410013, China
-
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
-
Zhejiang University College of Medicine Second Affiliated Hospital
Hangzhou, Zhejiang, 310009, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.